FDA approves Synergy's drug for chronic idiopathic constipation

The Food and Drug Administration on Thursday approved New York City-based Synergy Pharmaceuticals' drug for chronic idiopathic constipation.

Trulance is a once-daily treatment that works locally in the upper gastrointestinal tract to stimulate secretion of intestinal fluid and support regular bowel function, according to a release from the FDA. The drug is not intended for anyone under the age of 18.

"No one medication works for all patients suffering from chronic gastrointestinal disorders," said Julie Beitz, MD, director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research. "With the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition."

More articles on supply chain:

Poor countries permitted to import cheaper generics through new WTO amendment
Bristol-Myers Squibb reaches $625M settlement with Merck in Keytruda-Opdivo patent dispute
Trump initiates meeting with Rep. Elijah Cummings on high drug costs

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars